Schrödinger
120 West 45th Street
17th Floor
New York
NY
10036-4041
United States
Tel: 503-299-1150
Website: https://www.schrodinger.com/careers
Email: careers@schrodinger.com
151 articles about Schrödinger
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 18, 2024
4/18/2024
Schrödinger, Inc. today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees.
-
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
4/10/2024
Schrödinger will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 19, 2024
3/19/2024
Schrödinger, Inc. today reported that on March 15, 2024, the company granted (i) non-statutory stock options to purchase 40,400 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,550 shares of the company’s common stock to eight newly hired employees.
-
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
2/28/2024
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided its financial outlook for 2024.
-
Schrödinger to Participate in Upcoming Investor Conferences - February 20, 2024
2/20/2024
Schrödinger today announced that management will participate in the following conferences in March.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 16, 2024
2/16/2024
Schrödinger, Inc. reported that on February 13, 2024, the company granted non-statutory stock options to purchase 4,800 shares of the company’s common stock to four newly hired employees and restricted stock units with respect to 5,550 shares of the company’s common stock to eight newly hired employees.
-
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
2/14/2024
Schrödinger will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024, after the financial markets close.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 19, 2024
1/19/2024
Schrödinger, Inc. today reported that on January 16, 2024, the company granted (i) non-statutory stock options to purchase 6,825 shares of the company’s common stock to seven newly hired employees and (ii) restricted stock units (RSUs) with respect to 8,438 shares of the company’s common stock to 15 newly hired employees.
-
Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals
1/8/2024
Schrödinger, Inc., Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, provided an update on its progress across the business and announced its development and operational goals for 2024.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 19, 2023
12/19/2023
Schrödinger, Inc. today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees.
-
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event
12/14/2023
Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day , December 14, from 10:00 a.m. - 12:30 p.m. ET.
-
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
12/10/2023
Schrödinger announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, in a poster session at the American Society of Hematology 65th Annual Meeting taking place virtually and in San Diego, California.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)-November 17, 2023
11/17/2023
Schrödinger, Inc. today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050 shares of the company’s common stock to 13 newly hired employees.
-
Schrödinger to Participate in Upcoming Investor Conferences
11/6/2023
Schrödinger today announced that management will participate in the following conferences in November.
-
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
11/2/2023
Schrödinger today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, will be presented during a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place virtually and in San Diego, California, December 9-12, 2023.
-
Schrödinger Reports Third Quarter 2023 Financial Results
11/1/2023
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the quarter ended on September 30, 2023.
-
Schrödinger to Host Pipeline Day on December 14, 2023
10/30/2023
Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that the company will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m. ET.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 23, 2023
10/23/2023
Schrödinger, Inc. today reported that on October 17, 2023, the company granted (i) non-statutory stock options to purchase 9,150 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,625 shares of the company’s common stock to 14 newly hired employees.
-
Schrödinger to Announce Third Quarter 2023 Financial Results on November 1
10/18/2023
Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2023 financial results on Wednesday, November 1, 2023, after the financial markets close.
-
Copernic Catalysts Announces Research Collaboration With Schrödinger to Accelerate Sustainable Catalyst Discovery
10/3/2023
Copernic Catalysts, Inc. (Copernic) today announced an exclusive four-year research collaboration with Schrödinger, Inc. to help accelerate the discovery and development of sustainable catalysts for applications in e-fuels and bulk chemicals.